Visual Field Variability after Gene Therapy for Leber’s Hereditary Optic Neuropathy
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Purpose: To assess changes in visual field (VF) values after gene therapy for Leber’s hereditary optic neuropathy (LHON). Methods: VF recovery, VF indices, and mean deviation in injected and uninjected eyes, before and after gene therapy, were examined in 2 groups of patients according to disease duration (≤2 years and > 2 years). Nine patients with LHON were treated by monocular intravitreal injection of AAV2-ND4. Finally, 7 patients were considered for subsequent comparisons; the first and second eyes were treated separately. Results: There were no significant differences in VF indices and mean deviation between injected and uninjected eyes (p = 0.910 and p = 0.929, respectively). However, there was a significant difference before and after injection (p = 0.016 and p = 0.015, respectively). There was no significant difference in VF improvement between patients with ≤2 years’ disease duration and those with a longer disease duration. Conclusion: There was a statistically significant VF improvement after gene therapy. This suggests that monocular intravitreal injection of AAV2-ND4 can improve binocular VF values. This study also suggests that gene therapy can be effective in patients with a disease duration of > 2 years.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two similar gene therapy programmes led by groups in the USA25,26 and China,27–30 have targeted the m.11778G>A mutation in MT-ND4, also using a viral vector containing a cDNA coding the human wild-type mitochondrial ND4 protein.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [30]
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Mitochondrial optic neuropathies—Disease mechanisms and therapeutic strategies
Yu-Wai-Man, P., Griffiths, P. G., & Chinnery, P. F. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.11.002 · Cited by 633
A computerized method of visual acuity testing
Beck, R. W., Moke, P. S., Turpin, A. H., Ferris, F. L., SanGiovanni, J. P., Johnson, C. A., Birch, E. E., Chandler, D. L., Cox, T. A., Blair, R. C., et al. (2003) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01825-1 · Cited by 607
A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy.
Klopstock, T., Yu-Wai-Man, P., Dimitriadis, K., Rouleau, J., Heck, S., Bailie, M., Atawan, A., Chattopadhyay, S., Schubert, M., Garip, A., et al. (2011) · Brain · doi:10.1093/brain/awr170 · Cited by 578
Efficacy and Safety of rAAV2-ND4 Treatment for Leber’s Hereditary Optic Neuropathy
Wan, X., Pei, H., Zhao, M.-J., Yang, S., Hu, W.-K., He, H., Ma, S.-Q., Zhang, G., Dong, X.-Y., Chen, C., et al. (2016) · Scientific Reports · doi:10.1038/srep21587 · Cited by 182
Self-citationTreatment strategies for inherited optic neuropathies: past, present and future
Yu‐Wai‐Man, P., Votruba, M., Moore, A. T., & Chinnery, P. F. (2014) · Eye · doi:10.1038/eye.2014.37 · Cited by 151
Long-term outcomes of gene therapy for the treatment of Leber’s hereditary optic neuropathy
Yang, S., Ma, S.-Q., Wan, X., He, H., Pei, H., Zhao, M.-J., Chen, C., Wang, D.-W., Dong, X.-Y., Yuan, J.-J., et al. (2016) · eBioMedicine · doi:10.1016/j.ebiom.2016.07.002 · Cited by 139
Self-citationLam, B. L., Feuer, W. J., Schiffman, J. C., Porciatti, V., Vandenbroucke, R., Rosa, P. R., Gregori, G., & Guy, J. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.7971 · Cited by 96
Newman, N. J., Biousse, V., Newman, S. A., Bhatti, M. T., Hamilton, S. R., Farris, B. K., Lesser, R. L., & Turbin, R. E. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.12.045 · Cited by 56
Cited by
Newman, N. J., Yu-Wai-Man, P., Carelli, V., Moster, M. L., Biousse, V., Vignal-Clermont, C., Sergott, R. C., Klopstock, T., Sadun, A. A., Barboni, P., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2020.12.012 · Cited by 168
Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy
Newman, N. J., Yu-Wai-Man, P., Subramanian, P. S., Moster, M. L., Wang, A.-G., Donahue, S. P., Leroy, B. P., Carelli, V., Biousse, V., Vignal-Clermont, C., et al. (2023) · Brain · doi:10.1093/brain/awac421 · Cited by 87
Vignal-Clermont, C., Girmens, J.-F., Audo, I., Said, S. M., Errera, M.-H., Plaine, L., O’Shaughnessy, D., Taiel, M., & Sahel, J.-A. (2021) · BioDrugs · doi:10.1007/s40259-021-00468-9 · Cited by 51
Bahr, T. A., Welburn, K., Donnelly, J., & Bai, Y. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165743 · Cited by 47
Biodistribution of intravitreal lenadogene nolparvovec gene therapy in nonhuman primates
Calkins, D. J., Yu-Wai-Man, P., Newman, N. J., Taiel, M., Singh, P., Chalmey, C., Rogue, A., Carelli, V., Ancian, P., & Sahel, J. A. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.013 · Cited by 37
Metadata
- Authors
- Yuan, J.-J., Zhang, Y., Wang, L.-L., Cheng, M.-S., Ma, S.-Q., Gao, Q., & Li, B.
- Affiliations
- Hubei University of Medicine (CN)
- Huazhong University of Science and Technology (CN)
- Venue
- Ophthalmic Research
- Publisher
- S. Karger AG
- Published
- 2018
- Volume
- 60
- Issue
- 3
- Pages
- 176-184
- ISSN
- 0030-3747 (ISSN-L)
- 1423-0259
- OpenAlex
- W2895455275
- Cited by
- 17
- References
- 14
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 3 · 2022: 2 · 2021: 5 · 2020: 2 · 2019: 1
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Ophthalmic Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- Leber's hereditary optic neuropathy, gene therapy, intravitreal injection, visual field recovery, mean deviation, disease duration, binocular visual field, optic neuropathy
- MeSH terms
- Adolescent, Adult, Analysis of Variance, Child, Female, Genetic Vectors, Humans, Male, Middle Aged, Visual Acuity, Visual Fields, Genetic Therapy, Optic Atrophy, Hereditary, Leber, Young Adult, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Visual Field Variability after Gene Therapy for Leber’s Hereditary Optic Neuropathy. https://app.cochat.ai/papers/10.1159/000487485
- The paper
- Yuan, J.-J., Zhang, Y., Wang, L.-L., Cheng, M.-S., Ma, S.-Q., Gao, Q., & Li, B. (2018). Visual Field Variability after Gene Therapy for Leber’s Hereditary Optic Neuropathy. Ophthalmic Research. https://doi.org/10.1159/000487485
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.